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SUMMARY
Dried blood spots (DBS) are collected uniformly from U.S. newborns to test for metabolic and
other disorders. Because evidence exists for prenatal origins of some diseases, DBS may provide
unique prenatal exposure records. Some states retain residual DBS and permit their use in
etiologic studies. The primary study aim was to assess the feasibility of obtaining residual DBS
from state newborn screening programs for pediatric and adolescent cancer patients nationwide
with parental/subject consent/assent. Families of leukemia and lymphoma patients aged ≤21 years
diagnosed from 1998–2007 at randomly selected Children’s Oncology Group institutions across
the U.S. were queried (n=947). Parents/guardians and patients aged ≥18 years were asked to
release DBS to investigators in spring 2009. DBS were then requested from states. Overall, 299
families (32%) released DBS. Consenting/assenting patients were born in 39 U.S. states and 46
DBS were obtained from 5 states; 124 DBS were unobtainable because patients were born prior to
dates of state retention. State policies are rapidly evolving and there is ongoing discussion
regarding DBS storage and secondary research uses. Currently, population-based DBS studies can
be conducted in a limited number of states; fortunately, many have large populations to provide
reasonably sized pediatric subject groups.
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INTRODUCTION
Dried blood spots (DBS) are collected from nearly all neonates (>95%)1 in the U.S. per a
standard protocol2 to test for metabolic and other disorders.3 Newborn screening (NBS)
programs are mandated by U.S. states, resulting in considerable variability in
Address correspondence to: Julie A. Ross, Ph.D., Department of Pediatrics, University of Minnesota, 420 Delaware Street SE, MMC
422, Minneapolis, MN 55455; Telephone: 612-626-2902; Fax: 612-626-4842; rossx014@umn.edu.
Conflicts of Interest: The authors report no conflicts of interest regarding this research.
NIH Public Access
Author Manuscript
Paediatr Perinat Epidemiol. Author manuscript; available in PMC 2013 May 26.
Published in final edited form as:













implementation nationally.4, 5 Each state selects the tests to be performed, establishes
consent and refusal processes, and acts as a steward of residual DBS. Some states retain
residual DBS for ≥5 years, potentially permitting their use in etiologic research.5 There is
ongoing discussion among the public, NBS, and research communities, however, regarding
individual and societal benefits and potential risks of DBS storage and secondary research
uses.
Many childhood conditions, including cancers, are thought to have prenatal origins.6–10 One
important line of evidence in support of prenatal origins is the detection of chromosomal
translocations in DBS collected at birth from childhood leukemia cases.7, 8 These
translocations may constitute a first genetic hit in a multistep pathway,8 with subsequent hits
from endogenous or exogenous factors. It is therefore of keen interest to elucidate the role of
in utero exposures in carcinogenesis.
Recall bias is a potentially serious limitation of retrospective case-control studies of rare
pediatric/adolescent disorders. To our knowledge, DBS constitute the only consistent source
of prediagnostic biospecimens for affected children, and for a representative population of
control children, and may provide an unbiased record of in utero exposures, since they are
collected at birth. Their potential research value is great since theoretically, any substrate
measured in whole blood or blood products can also be analyzed in DBS.1 Accordingly,
several analytes have been evaluated in DBS, such as amino acids, enzymes, human and
viral DNA, antibodies, markers of inflammation, steroids, metals, protein adducts, pesticides
and cotinine.1, 11–14
Prior studies assessing DBS retrieval have been limited to single states and did not include
study-specific subject consent processes prior to specimen retrieval.15–17 Our primary aim
was to assess the feasibility of obtaining 1) parental/subject consent/assent for DBS release
from childhood/adolescent hematologic cancer cases on a nationwide basis and 2) DBS from
state newborn screening programs.
METHODS
Patients were eligible for this Children’s Oncology Group (COG) study (AEPI08N1) if they
were diagnosed with leukemia or lymphoma at 0–21 years of age in 1998–2007, were born
in the U.S., and they or their parent/guardian participated in a prior COG protocol
(AADM01P1),18 agreed to future contact, and spoke English or Spanish. Parents/guardians
of deceased patients were eligible.
Briefly, the prior COG protocol (AADM01P1) from which eligible subjects were identified
was conducted at a 10% random sample of COG institutions in North America (n=23).
Between May 2001 and January 2007, 2,233 families of childhood cancer cases were
approached and 2,136 (96%) agreed to future contact regarding COG-approved non-
therapeutic studies. Since COG institutions treat the vast majority of leukemia and
lymphoma cases ages 0–14 years in the U.S.19, 20 and since nearly all families agreed to
future contact, the use of this dataset in subject ascertainment provided a reasonably
representative sample of cases.
COG diagnosing institutions were provided with study summaries and were asked to either
supply last known contact information for parents/guardians or subjects providing consent
for future contact, or any reasons why families should not be contacted (e.g., child recently
died). Of note, contact information provided by COG institutions was last verified several
years prior for many families. Families were contacted in a series of mailings (introductory
letter, study packet, reminder/thank you postcard) over a period of 4 weeks in the spring of
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2009, followed by a phone call and/or a final mailing (second study packet). Spanish
translations were sent to known Spanish speakers.
Parents/guardians of children <18 years and deceased children were provided with a
description of the study and were asked to consider three levels of written consent, including
release of their child’s DBS to study investigators for prenatal exposure assessment, long-
term DBS storage by investigators, and future contact regarding this study. For children ≥18
years, contact information was requested (from parents/guardians) so they could be asked to
provide consent regarding their own DBS. Children ages 8–17 years were asked to provide
written assent, as children possessing the cognitive ability and maturity to comprehend a
research study should be given the autonomy to decide about their participation. In addition,
biological mothers, if available, were asked to complete self-administered questionnaires
regarding prenatal exposures and birth characteristics.
Non-respondents were traced via telephone and reverse directories and on-line methods.
Multiple attempts were made to reach non-respondents via telephone at different times of
day/days of the week; voicemail/answering machine messages were left on third or
subsequent failed attempts. Families who did not respond via mail, who were not reached
via telephone, and whose outgoing message did not clearly identify them were classified as
“contact unknown,” given that the U.S. Postal Service would not return study materials to
sender for addresses that had expired several years prior.
State newborn screening programs were provided with signed consent/assent forms and
asked to release DBS. States were also asked to provide DBS retention, storage, and release
policies. We contacted states of birth for all participating cases (39 states) regardless of prior
responses to surveys,4, 5 as state policies are evolving.
The protocol was approved by the Institutional Review Boards of the University of
Minnesota and of states releasing DBS, as needed.
Statistical analysis
Primary outcomes are the proportions of families consenting to DBS release and proportions
of DBS retrieved. Three “rates” (contact, cooperation, and response) were calculated as
outlined by Slattery et al21 to facilitate discussion of results. Contact rates are the proportion
of the total sample for whom contact was established, while cooperation rates are the
proportion of those contacted that participated, and response rates are the proportion of the
total that participated. Thus, response rates are equal to contact rates multiplied by
cooperation rates.
Univariate unconditional logistic regression (SAS v9.2, SAS Institute, Cary, North Carolina)
was also performed to assess whether baseline participant characteristics (shown in Table 1)
were statistically significant predictors of consent, assent, provision of adult child contact
information, questionnaire completion, or DBS retrieval; odds ratios (ORs) and 95%
confidence intervals (CIs) were produced. In addition, multivariable logistic regression was
performed to determine the significance of predictors after adjustment for all other factors.
RESULTS
Nineteen U.S. COG institutions provided contact information and reasons not to contact
subjects, while 2 refused for administrative reasons (1 institution was no longer participating
in COG and 1 had closed the original AADM01P1 study with their IRB and could not
prioritize reopening it) and 2 Canadian institutions were excluded (Canada has no provision
to provide DBS). Figure 1 provides a flow diagram for subject eligibility and participation.
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Of 1,006 hematologic cancer cases in the original AADM01P1 dataset, contact was
attempted for 947 in the current study.
For most of the 947 families, the first points of contact were mothers (94%) and English
speakers (93%) (Table 1). Forty percent of cases were diagnosed at <5 years and
approximately 20% were diagnosed in the other age categories. Half were born in 1997 or
thereafter (48%), while 59% were diagnosed ≥5 years prior to contact (median=5 years).
Most cases were last known to be alive (89%).
Contact, response, and cooperation rates are summarized in Table 2. Of the 947 families,
385 participated in some manner, resulting in an overall response rate of 41%, while 27
actively refused (3%) and materials from 57 were returned to sender (6%). An additional
165 were passive refusals (17%), meaning contact was confirmed via telephone. It was
unknown if contact was made with the remaining 313 (33%) (see Methods for further
information).
Fifty-four percent of parents/guardians of children ≥18 years at the time of contact provided
names and addresses. In addition, 3 subjects were adults (≥18 years) at diagnosis and had
provided consent for future contact, for a total of 135 adult children queried.
Thirty-seven percent of families returned signed consent forms, including 228 mothers
(34%), 7 parent/guardians (21%), and 75 adult children contacted upon receipt of
information from parents/guardians (57%). (Only 1 of 3 adult subjects was successfully
contacted and passively refused participation.) Of those providing consent, 304 agreed to
DBS release, storage, and future contact, while 2 agreed to release and storage, 2 agreed to
release and future contact, and 2 agreed to release only. One consent was signed by a minor
and written consent could not be obtained from that parent/guardian. Families of cases
diagnosed at 15–20 years and cases born in 1987–1991 were approximately 2 times more
likely to consent compared to cases aged 0–4 years (OR=1.95, 95% CI:1.28, 2.97), and
those born in 1997–2001 (OR=2.08, 95% CI:1.38, 3.15), respectively. Spanish speakers
were significantly less likely to consent than English speakers (OR=0.33, 95% CI:0.14,
0.75). Upon adjustment for all factors, only Spanish language remained a significant
predictor of response (OR=0.32, 95% CI:0.14, 0.74).
Thirty-two percent of children ages 8–17 years returned signed assent forms (n=148). In
addition, 7 were signed by parents/guardians and signed assents were not obtained from
these children.
Forty-one percent of mothers returned completed questionnaires. Notably, 82% of families
providing completed questionnaires also returned signed consents for DBS release. Similar
to consent response, diagnosis at ages 15–20 years (OR=2.05, 95% CI:1.41, 2.98), birth in
the years 1987–1991 (OR=1.85, 95% CI:1.29, 2.66), and Spanish language (OR=0.39, 95%
CI:0.19, 0.79) were significant predictors of questionnaire completion. Spanish language
was the only significant predictor in the multivariable model (OR=0.38, 95% CI:0.19, 0.79).
Respondents were born in 42 U.S. states and those providing consent for DBS release were
born in 39 of these. DBS were requested for 299 cases (and were not requested for 7 missing
signed assents and 4 not born in the U.S.). Of 39 states queried, 5 (CA, MI, NY, TX, WA)
released 46 DBS (Figure 2). (The specimens await analysis for prenatal exposures.) These
states did not have DBS for 12 “age-ineligible” cases (those born prior to oldest date of state
retention) and could not locate spots for 2 age-eligible cases based on the information
provided (child’s last name, date of birth, mother’s full name, hospital name and city). None
of the factors examined were significant predictors of DBS retrieval, although this may be
attributable to the small number of retrieved spots.
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DBS were unobtainable for 112 cases because states store spots for <1 year (n=72, AZ, GA,
IL, LA, NE, OK, PA, UT, VA, WY), 1-<5 years (n=33, AK, DE, ID, MT, NM, NV, OH,
TN, WI) or ≥5 years (n=7, IA, IN, MD, ME, MO, NC) and cases were age-ineligible. Of
note, policies may not allow for DBS retrieval in 5 of these (GA, IL, NM, NV, WY).
Policies in 6 states (CT, FL, MS, OR, SD, VT) do not allow for release of identifiable DBS
for research (n=60). Requests are pending in 3 states (n=67), including one involved in
ongoing litigation unrelated to the current study (MN), a second currently reviewing its
storage/release policies (NJ), and a third performing a protocol review (MA). Supplementary
Table 1 (available online) summarizes length of retention, willingness to release spots with
written consent, and storage conditions for the 39 queried states.
DISCUSSION
In this national feasibility study, 37% of families of pediatric and adolescent cancer patients
contributed written consent/assent authorizing DBS release to investigators and 39 state
NBS programs were approached with signed consent/assent forms. This response rate may
not accurately portray subject interest in DBS research, however, since we are unable to
determine whether one-third of families were reached. When we calculated cooperation
rates based on families with confirmed contact, the consent rate was considerably higher
(58%, Table 2). Nevertheless, due to limited state retention and release practices, DBS were
retrieved for only a small fraction of those requested (46/299, 15%). Notably, at least 25 of
the 39 queried states were willing to release DBS with subject consent. However, in most of
the states DBS were not stored long enough to permit their release.
Families of older cases and those diagnosed less recently were more likely to participate.
This pattern may signal limitations on subjects’ time, as families with younger children
anecdotally indicated in telephone conversations with interviewers that time constraints
were preventing them from participating. Spanish-speaking subjects were also less likely to
participate after adjustment for all other factors, although materials were provided in their
native language. These results likely reflect the greater inability to reach these families
(materials were returned to sender in 20% of families and no contact was established in 59%
of families vs. 5% and 32%, respectively, in English-speaking families). It is also possible
that most families were reached and elected not to respond, which might signify a lack of
trust in this research.22, 23
This was also the first DBS study to assess participation of subjects ages ≥18 years, in whom
higher levels of consent were observed compared with parents/guardians. Notably, adult
children would have been aware of their cancers as they were diagnosed 2–9 years prior to
the current study. They may not have had complete autonomy with regard to their
participation, however, since parents/guardians were the initial points of contact for most.
Presumably, if parents/guardians could not be reached, were opposed to DBS research, or
did not wish for their adult children to be asked about this study, no contact information was
provided, and adult children were not asked. Conversely, very interested parents/guardians
may have placed expectations on their children regarding participation. Similar to our
results, a prior survey of adult subjects’ attitudes indicated that a majority would be willing
to provide consent for research on their pediatric specimens.24 Future studies should attempt
to contact adult subjects directly to remove the parental element from the decision.
A complex array of ethical considerations is implicated with the storage and use of DBS for
secondary research purposes. As such, this topic is currently the subject of active dialogue
on a national level, with a focus on balancing societal/public health benefits and respect for
individuals.4, 25, 26 Although limited, the available evidence indicates support for DBS
storage and research among the general public,27–29 and among NBS professionals and
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researchers,12, 30–32 with some caveats. For example, a majority of participants in a
nationally representative survey of parental attitudes27 and a Michigan citizen’s deliberative
jury28 supported DBS storage and release if their permission was sought. Far fewer were
amenable to research conducted without permission, however. Notably, no consent forms or
DBS were collected in those studies.27, 28
There are important ethical considerations with respect to NBS itself (see 33). Ensuring
universal screening is of primary importance to NBS programs, in order to protect children
from rare debilitating and/or potentially fatal conditions by early detection and
intervention.32 Thus, secondary research uses of DBS should not interfere with this core
mission.32
Residual DBS are a fortunate NBS byproduct that could be used to facilitate valuable
research on additional debilitating and/or fatal conditions, if the difficult outstanding ethical
issues could be addressed in a manner acceptable to all stakeholders. A principal area of
concern is ownership of the spots. DBS ownership is assigned to the state in 5 states, while 5
others classify genetic information as personal property.31 Regardless of formal policies/
laws, however, parents or children may feel ownership regarding DBS28, 29 and/or genetic
information generated from them. DNA can be extracted from DBS, potentially allowing
individual and/or familial disease susceptibility to be uncovered. Thus, research on
identifiable specimens could lead to loss of privacy, psychological harms, or discrimination
by third parties (e.g., employers or insurance providers),25, 34 although there have been no
documented abuses to date.31 Other important concerns involve failure to disclose and
obtain active consent for long-term storage and secondary uses, timing and type of consent
needed (e.g., blanket vs. study-specific), insufficient security measures, potential
government and/or forensic uses, potential to reveal paternity, inequitable distribution of
research benefits, and the potential for group-level harms4, 25, 26, 32. Many of these issues
suggest a need for increased transparency, oversight, and education to improve public
trust.32, 35 Notably, 12 states describe DBS storage and release policies in education
materials, and a minority have explicit consent mechanisms for future use.28, 31
If the unresolved concerns are not adequately addressed, public unease may lead to lower
NBS rates and/or reduced DBS availability. For example, genetic privacy advocacy groups
sued the states of Texas and Minnesota in 2009, calling for destruction of specimens stored
without explicit parental consent.36, 37 Although DBS were spared for our study, the Texas
settlement resulted in the destruction of 5 million DBS.38 A second lawsuit has recently
been filed by the same plaintiffs.39 The Minnesota lawsuit was dismissed40 but an appeal
has recently been filed with the state supreme court. Other states are reviewing their policies
(see Supplementary Table 1), presumably due to similar concerns. Importantly,
recommendations have recently been issued to assist states as they develop comprehensive
DBS policies.31
Other factors have been associated with DBS acquisition. In our study, there was no obvious
explanation for the 2 unretrievable spots in states providing DBS; identical data were
provided for these cases as for those with retrieved specimens. In a prior study conducted in
Maryland, significantly lower retrieval rates were observed among cases with congenital
heart defects (65%) than among population-based controls (84%).17 Among controls, a
sizable number either had no laboratory number linking participants and DBS (10%) or
could not be located (6%). Observed retrieval rates were also significantly lower among low
birthweight and preterm infants.
This study features unique strengths. To our knowledge, it is the first U.S. study to attempt
DBS retrieval with parental/subject consent/assent on a national level. Study-specific
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consent/assent allowed subjects to evaluate content of proposed research28 and measures to
protect privacy/confidentiality. Additionally, the randomly selected study population should
reasonably represent U.S. pediatric/adolescent cancer cases, as described above.
Correspondingly, consenting cases were born in 39 states, providing an excellent survey of
the national feasibility of this methodology. Further, it included children ≥18 years, although
many were not approached because parents/guardians were not reached or chose not to
provide contact information. Finally, these results are applicable to etiologic studies of other
rare pediatric/adolescent conditions requiring retrospective designs.
The chief limitation is that state DBS policies are continually evolving; this report represents
a snapshot in time. Some states have recently passed legislation allowing long-term storage
of DBS (Supplementary Table 1). Conversely, 2 states are involved in ongoing legislation
due to data privacy concerns, resulting in destruction of stored DBS in 1, and others are
reviewing their policies. Additionally, the sizable proportion of families for whom contact
was uncertain limits calculation of accurate response and cooperation rates and
generalizability of results. Failure to reach these families is likely a function of the dataset
used in case ascertainment, as subjects were diagnosed up to 10 years prior. We have
anecdotally observed that a cancer diagnosis in a child can induce financial turmoil and
familial instability, leading to transient housing situations and therefore, difficulty in
locating families for research. We anticipate that the use of a dataset involving a more
recently diagnosed patient population would greatly minimize this concern, as treating
institutions would have current contact information for subjects in active treatment or
follow-up. Notably, 82% of families returning questionnaires also released DBS, indicating
high participation levels if families are reached and engaged. Lastly, etiologic studies of
pediatric/adolescent cancers usually utilize retrospective case-control designs, however, we
limited the scope of this initial feasibility study to families of cases who had agreed to future
contact regarding research. Parents of healthy children may not be aware of the importance
or utility of DBS research27 or may prioritize data privacy concerns over desire to
participate and therefore may be less likely to participate. Consistent with this idea, Tarini et
al found that parents with children with very good and excellent health reported they would
be less likely to agree to DBS release or storage.27 An alternate control strategy may be the
use of randomly selected, anonymized DBS from states of birth of cases. Future research
should address the need for DBS from healthy controls.
From a research perspective, DBS from all U.S. infants would ideally be cataloged and
properly stored such that they could be retrieved and released with appropriate scientific
justification, ethics review board oversight, and subject consent. In practice, state retention
policies are evolving. In our experience, DBS studies of pediatric conditions are currently
limited to a few states. Fortunately, most have large populations to provide reasonable
pediatric sample sizes. Depending on subject ages and future policies, research may be
possible in additional states storing DBS ≥5 years. Studies of conditions in young children
may have the greatest success and relevance to prenatal exposures. It will be of interest to
observe state policies as they unfold.
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Flow Diagram of Subject Participation and Dried Blood Spot Retrieval for 947 Families of
Pediatric and Adolescent Hematologic Cancer Cases and 39 State Newborn Screening
Programs, United States, 2009–2010.
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State Newborn Screening Program Policies on Residual Dried Blood Spot Retention and
Release for 39 Queried States, United States, 2009–2010. Black = DBS retrieved, dotted =
request pending, dark gray = DBS stored ≥5 years, gray = DBS stored 1-<5 years, light gray
= DBS stored <1 year, hatched = refused, white = not queried. (United States map courtesy
of Minnesota Population Center. National Historical Geographic Information System: Pre-
release Version 0.1. Minneapolis, MN: University of Minnesota 2004 (http://
www.nhgis.org). Shading via ArcGIS mapping software version 9.3, Esri, Relands,
California.)
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Table 1




 Mother 887 (93.7)
 Parent/Guardian 57 (6.0)
 Child ≥18 years at diagnosis 3 (0.3)
Language
 English 877 (92.6)
 Spanish 46 (4.9)
 Unknown 24 (2.5)
Age at diagnosis
 0–4 years 375 (39.6)
 5–9 years 204 (21.5)
 10–14 years 181 (19.1)
 15–20 years 187 (19.8)
Year of birth
 1982–1986 86 (9.1)
 1987–1991 208 (22.0)
 1992–1996 197 (20.8)
 1997–2001 326 (34.4)
 2002–2006 130 (13.7)
Years since diagnosis
 2–4 years 386 (40.8)
 5–10 years 561 (59.2)
Vital status
 Alive 844 (89.1)
 Deceased 83 (8.8)
 Unknown 20 (2.1)
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